Upperton Pharma Solutions, a U.K.-based CDMO, put the finishing touches on a 15 million pound sterling ($19.6 million) expansion of its manufacturing facility near its headquarters in Nottingham.
With the project, Upperton now boasts a 50,000-square-foot footprint, the company said in a July 12 press release.
Pending regulatory approvals and other operational milestones, Upperton expects the facility to be fully operational by the end of the year and to begin production in January 2024.
The plant will feature powder blending up to 250 kilograms per batch, capsule filling at up to 40,000 capsules an hour, dry granulation processing of up to 100 kilograms an hour and the ability to press as many as 120,000 tablets an hour.
“By increasing the scale at which we can operate, we are looking forward to being able to offer our customers a smooth transition from early development, to clinical trials and commercial manufacturing for low volume, niche products—all at one, single site, with established project teams,” Nikki Whitfield, Upperton’s chief executive, said in the release.
Founded in 1999, Upperton says it offers a range of services from dosage form development to clinical trial manufacturing.